Skip to main content

Table 1 Correlation between miR-29c expression and patients’ parameters

From: Down-regulation of miR-29c is a prognostic biomarker in acute myeloid leukemia and can reduce the sensitivity of leukemic cells to decitabine

Patient’s parameters Status of miR-29c expression
Low (n = 51) High (n = 51) P
Sex, male/female 31/20 29/22 0.423
Median age, years (range) 54 (19–93) 58 (18–87) 0.968
Median WBC, × 109/L (range) 12 (1.1–201) 8.1 (0.3–528) 0.517
Median hemoglobin, g/L (range) 76.5 (34–138) 71 (32–113) 0.202
Median platelets, × 109/L (range) 42 (3–447) 37 (4–399) 0.196
BM blasts, % (range) 53 (6.5–94.5) 42.5 (1.0–97.5) 0.085
FAB classification 0.002
 M0 1 0  
 M1 5 4  
 M2 23 24  
 M3 1 14  
 M4 14 6  
 M5 6 3  
 M6 1 0  
WHO classification 0.007
 t (8;21) 7 5  
 t (15;17) 1 13  
 AML without maturation 4 4  
 AML with maturation 18 18  
 Acute myelomonocytic leukemia 15 7  
 Acute monoblastic and monocytic leukemia 5 2  
 Acute erythroid leukemia 1 0  
 No data 0 2  
Risk classification 0.013
 Low 8 20  
 Intermediate 35 23  
 High 8 4  
 No data 0 4  
Karyotype 0.006
 Normal 27 18  
 t (8;21) 7 7  
 t (15;17) 1 13  
 11q23 1 0  
 Complex 7 4  
 Others 8 5  
 No data 0 4  
Gene mutation*
 C-KIT (±) 2/47 1/47 1.000
 FLT3 (±) 7/42 6/42 1.000
 NPM1 (±) 5/44 5/43 1.000
 C/EBPA (±) 7/42 5/43 0.759
 N/K-RAS (±) 3/46 4/45 1.000
 IDH1/2 (±) 3/46 3/40 0.704
 DNMT3A (±) 6/43 3/40 0.494
 U2AF1 (±) 1/48 4/39 0.332
 CR (±) 33/17 26/21 0.305
  1. WBC white blood cells, FAB French–American–British classification, AML acute myeloid leukemia, CR complete remission
  2. +: positive; −: negative
  3. * +: bi-allelicmutation; −: mono-allelic mutation or wild type